On June 29, 2017, the development of Laipushutai, the class I innovative medicine with the cooperative development of JYMed and Guangzhou Linkhealth Medical Technology Co., Ltd., has made significant progress. The drug’s IND declaration has been accepted by the CFDA.
JYMed and Guangzhou Linkhealth Medical Technology Co., Ltd. reached a cooperation agreement in 2016 to jointly develop this product in China. The species has completed POC clinical studies in the EU and achieved good safety and remission rates. Both the FDA and the EMA recognize that this species can be applied for treatment on the I/II line, and priority will be given to the relief and treatment of patients with moderate ulcerative colitis in follow clinical trials of CFDA.
Ulcerative colitis (UC) is a chronic, non-specific inflammatory disease that occurs in the rectum and colon. According to statistics, the incidence rate of UC is 1.2 to 20.3 cases / 100,000 person per year and the prevalence of UC is 7.6 to 246.0 cases/10,000 people per year. The incidence of UC is more common in young adults. The UC market has large scale and demand for drugs, and will continue to maintain a high growth trend in the future. So far, UC first-line drug is mainly based on mesalazine and hormones, and second-line drugs include immunosuppressants and biological monoclonal antibodies. Mesalazine has a sales volume of 1 billion in China and US$2 billion in the United States in 2015. Laipushutai has a better response to UC symptoms, and is safer than the current first-line drugs. It has a good market advantage and is expected to become a first-line UC drug.